Allarity Therapeutics, Inc.
ALLRNext catalyst
2X-121
Advanced Ovarian Cancer
Get an email about ALLR's next catalysts
Track Allarity Therapeutics (ALLR) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 1 past
ALLR Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.21 | FQ end Sep/2026 | Call: tbd
2X-121 Phase 2 Est. Readout
Primary completion for 2X-121 trial (NCT03878849) in Advanced Ovarian Cancer
SourceMarket Overview
Stock performance and key metrics
2X-121
Advanced Ovarian Cancer
PARP inhibitor 2X-121
Metastatic Breast Cancer
Irofulven
Metastatic Castration-Resistant Prostate Cancer Patients
LiPlaCis
Phase 1: Advanced or Refractory Solid Tumours
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
2X-121 | Phase 2 | Advanced Ovarian Cancer | - | - |
PARP inhibitor 2X-121 | Phase 2 | Metastatic Breast Cancer | - | - |
Irofulven | Phase 2 | Metastatic Castration-Resistant Prostate Cancer Patients | - | - |
LiPlaCis | Phase 2 | Phase 1: Advanced or Refractory Solid Tumours | - | - |
Frequently asked questions
What is in Allarity Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Allarity Therapeutics, Inc.'s (ALLR) pipeline across Phase 2. Its lead program is 2X-121 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Allarity Therapeutics, Inc.'s next FDA catalyst?→
Allarity Therapeutics, Inc.'s (ALLR) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALLR biotech catalysts?→
Add ALLR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Allarity Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.